Showing results (1701-1710 of 1,799) with videos related to
Sort By:
Pageof 180
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patientsMichal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.Neurology|March 17, 2000
Vagus nerve stimulation therapy for epilepsy in older adultsJ I Sirven, M Sperling, D Naritoku, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.The Journal of Clinical Investigation|June 4, 2013
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growthYael Nemlich, Eyal Greenberg, Rona Ortenberg, et al.Epilepsy & Behavior : E&B|June 15, 2013
Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)Amos D Korczyn, Steven C Schachter, Martin J Brodie, et al.Pageof 180